A Clinical Review of Cannabis Therapeutics: What the Evidence Actually Supports

As of 2025, strong evidence supports cannabis for chemotherapy nausea, HIV appetite loss, specific epilepsies, and MS spasticity, while evidence for pain, insomnia, and psychiatric conditions remains mixed.

Zhai, Xiadi et al.·Polish archives of internal medicine·2025·Moderate EvidenceReview
RTHC-08031ReviewModerate Evidence2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

Key established indications include chemotherapy-induced nausea/vomiting, HIV/AIDS appetite loss, Dravet/Lennox-Gastaut/tuberous sclerosis seizures, and MS spasticity. Evidence for chronic pain, insomnia, and psychiatric disorders is inconclusive. Risks include addiction, cognitive impairment in adolescents, CHS, psychosis, perinatal complications, and cardiovascular/pulmonary effects.

Key Numbers

Established indications: 6 conditions with strong evidence. Emerging areas with mixed evidence: chronic pain, insomnia, opioid use disorder, neurological disorders.

How They Did This

Clinical review evaluating current evidence for cannabis and cannabinoid treatment across established and emerging indications, with assessment of known risks and harms.

Why This Research Matters

As public interest in medical cannabis grows, clinicians need a clear evidence-based framework for what cannabis can and cannot do. This review separates established benefits from hype and honestly addresses risks.

The Bigger Picture

The gap between public perception of cannabis as medicine and actual clinical evidence remains significant. This review provides clinicians with the balanced assessment needed to counsel patients who increasingly arrive having already tried cannabis.

What This Study Doesn't Tell Us

Review scope limited to selected conditions. Cannabis research is hampered by historical scheduling restrictions. Evidence quality varies dramatically across conditions.

Questions This Raises

  • ?Will improved research access lead to more established indications?
  • ?How should clinicians handle the gap between patient experience and clinical evidence?

Trust & Context

Key Stat:
Evidence Grade:
Comprehensive clinical review providing an up-to-date evidence synthesis, though dependent on available research which remains limited for many conditions.
Study Age:
2025 review providing the most current clinical evidence assessment for cannabis therapeutics.
Original Title:
Therapeutic use of cannabis and cannabinoids: benefits and risks.
Published In:
Polish archives of internal medicine, 135(11) (2025)
Database ID:
RTHC-08031

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

What conditions does cannabis actually help?

Strong evidence supports: chemotherapy nausea, HIV appetite loss, Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis seizures, and MS spasticity. Evidence for pain, sleep, and psychiatric conditions remains mixed.

What are the main risks of cannabis use?

Key risks include addiction potential, cognitive impairment (especially in adolescents), cannabinoid hyperemesis syndrome, psychosis risk, pregnancy complications, and cardiovascular/pulmonary effects.

Read More on RethinkTHC

Cite This Study

RTHC-08031·https://rethinkthc.com/research/RTHC-08031

APA

Zhai, Xiadi; Sarkar, Pooja R; Hill, Kevin P. (2025). Therapeutic use of cannabis and cannabinoids: benefits and risks.. Polish archives of internal medicine, 135(11). https://doi.org/10.20452/pamw.17117

MLA

Zhai, Xiadi, et al. "Therapeutic use of cannabis and cannabinoids: benefits and risks.." Polish archives of internal medicine, 2025. https://doi.org/10.20452/pamw.17117

RethinkTHC

RethinkTHC Research Database. "Therapeutic use of cannabis and cannabinoids: benefits and r..." RTHC-08031. Retrieved from https://rethinkthc.com/research/zhai-2025-therapeutic-use-of-cannabis

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.